John Kirkikis, MD
Gastroenterology · Shreveport, LANPI 1700869724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 389 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,446 and has fallen 50.2% since, to $720 in 2025.
Across 389 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$925
- Takeda Pharmaceuticals U.S.A., Inc.$545
- Pfizer$525
- Sanofi$285
- plus $1K from 21 others
What the payments were for
- Food & beverage$6,491100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,447 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 103 | $1,447 |
| Johnson & Johnson | 50 | $925 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $545 |
| Pfizer | 34 | $525 |
| Sanofi | 12 | $285 |
| Merck | 15 | $233 |
| Daiichi Sankyo Inc. | 13 | $226 |
| Bristol Myers Squibb | 9 | $142 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Lilly USA, LLC | 5 | $79 |
| Ironwood Pharmaceuticals, Inc | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Intercept Pharmaceuticals, Inc. | 3 | $55 |
| Cumberland Pharmaceuticals, Inc. | 3 | $49 |
| Evoke Pharma, Inc. | 2 | $45 |
| Amgen | 2 | $44 |
| UCB, Inc. | 2 | $35 |
| AstraZeneca | 1 | $33 |
| Redhill Biopharma Inc. | 2 | $30 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Gilead | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Sandoz | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
How this compares
$6,499 in reported general payments places this provider in the 70th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Shreveport
- Humberto AguilarShreveport$313K
- Hrishikesh SamantShreveport$81K
- Sathya JaganmohanShreveport$25K
- Qiang CaiShreveport$14K
- Elvin HardyShreveport$13K
- James MorrisShreveport$11K
- John ProvenzaShreveport$9K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.